Age and aging in blood disorders: multiple myeloma
- PMID: 24986875
- PMCID: PMC4077073
- DOI: 10.3324/haematol.2014.110296
Age and aging in blood disorders: multiple myeloma
Similar articles
-
Novel therapies for multiple myeloma.Aging (Albany NY). 2017 Aug 28;9(8):1857-1858. doi: 10.18632/aging.101284. Aging (Albany NY). 2017. PMID: 28854147 Free PMC article. No abstract available.
-
Plasmazell-Myelom.Praxis (Bern 1994). 2016;105(21):1255-1260. doi: 10.1024/1661-8157/a002493. Praxis (Bern 1994). 2016. PMID: 28573955 Review. German. No abstract available.
-
Clinical characteristics of patients with relapsed multiple myeloma.Cancer Treat Rev. 2015 Dec;41(10):827-35. doi: 10.1016/j.ctrv.2015.07.005. Epub 2015 Jul 31. Cancer Treat Rev. 2015. PMID: 26296679 Review.
-
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20. Blood. 2018. PMID: 30237154 Free PMC article. Clinical Trial. No abstract available.
-
Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.Ann Hematol. 2019 Mar;98(3):793-795. doi: 10.1007/s00277-019-03614-0. Epub 2019 Jan 15. Ann Hematol. 2019. PMID: 30645676 No abstract available.
Cited by
-
Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.Cancer Med. 2020 Jan;9(2):626-639. doi: 10.1002/cam4.2698. Epub 2019 Dec 4. Cancer Med. 2020. PMID: 31801177 Free PMC article.
-
Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance.Cancers (Basel). 2023 Mar 9;15(6):1682. doi: 10.3390/cancers15061682. Cancers (Basel). 2023. PMID: 36980568 Free PMC article. Review.
-
Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.J Frailty Aging. 2019;8(4):215-221. doi: 10.14283/jfa.2019.25. J Frailty Aging. 2019. PMID: 31637409 Free PMC article. Review.
-
Tretatment approach of nontransplant patients with multiple myeloma.Mater Sociomed. 2014 Oct;26(5):348-51. doi: 10.5455/msm.2014.26.348-351. Epub 2014 Oct 29. Mater Sociomed. 2014. PMID: 25568637 Free PMC article. Review.
-
Aging and blood disorders: new perspectives, new challenges.Haematologica. 2015 Apr;100(4):415-7. doi: 10.3324/haematol.2015.126771. Haematologica. 2015. PMID: 25828087 Free PMC article. No abstract available.
References
-
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60 - PubMed
-
- Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. 2013;163(1):40–6 - PubMed
-
- Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519–29 - PubMed
-
- San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448–55 - PubMed
-
- Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239–47 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical